文献速递肿瘤 PET/CT神经核医学核素与放射性配体治疗

脑肿瘤患者中PET的可及性与使用情况:欧洲癌症研究与治疗组织脑肿瘤组(EORTC-BTG)调查

Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-04

该横断面在线调查于2024年6月至8月由EORTC-BTG成员完成,共收到来自20个国家的103份回复。96/103(93.2%)的机构有PET设施,其中74家(77.1%)在脑肿瘤患者中使用PET;氨基酸PET在62/71家中心(87.3%)开展,SSTR PET在50/68家中心(73.5%)开展。作者结论认为PET在神经肿瘤中的应用在各EORTC-BTG机构间存在差异,需要临床试验证据及纳入非学术机构的调查来指导临床实践。

要点

  • 103份回复中96家(93.2%)有PET设施,74家(77.1%)在脑肿瘤患者中使用PET。
  • 氨基酸PET在62/71家中心(87.3%)开展,最常用于胶质瘤(58/59,98.3%)及鉴别治疗相关改变与肿瘤进展(58/59,98.3%)。
  • SSTR PET在50/68家中心(73.5%)开展,主要用于脑膜瘤(48/49,98.0%)及放射性配体治疗前患者筛选(41/49,83.7%)。

核心结论

  • PET在神经肿瘤中的应用在各EORTC-BTG机构间存在差异。
  • 需要开展临床试验获取证据并纳入非学术机构进行调查,以指导临床实践中的实施。

研究设计与样本

  • 欧洲癌症研究与治疗组织脑肿瘤组(EORTC-BTG)成员于2024年6月至8月完成的横断面在线调查,共收到来自20个国家的103份回复。

主要发现

  • 96/103(93.2%)的机构有PET设施,其中74家(77.1%)在脑肿瘤患者中使用PET。
  • 未开展PET的原因包括示踪剂可及性有限(14/29,48.3%)、费用高(11/29,37.9%)及认为PET不必要(8/29,27.6%)。
  • 开展PET的机构中,69/74(93.2%)用于胶质瘤,58/74(78.4%)用于脑转移瘤,52/74(70.3%)用于脑膜瘤,46/74(62.2%)用于中枢神经系统淋巴瘤。
  • 氨基酸PET在62/71家中心(87.3%;3家未报告)开展,最常用于胶质瘤(58/59,98.3%,3家未报告)及鉴别治疗相关改变与肿瘤进展(58/59,98.3%)。
  • SSTR PET在50/68家机构(73.5%,6家未报告)开展,主要用于脑膜瘤(48/49,98.0%)、放射性配体治疗前患者筛选(41/49,83.7%)及放疗靶区定义(33/49,67.3%)。

关键数值与推荐

  • 法定健康保险无限制覆盖:氨基酸PET为46/59家中心(78.0%),SSTR PET为33/49家中心(67.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Positron emission tomography (PET) is increasingly used in neuro-oncology. However, little is known about its application across European institutions and reasons for variable implementation. METHODS: Between June and August 2024, members of the European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) completed a cross-sectional online survey on PET use in neuro-oncological practice. RESULTS: Overall, 103 replies from 20 countries were received. A PET facility was available at 96/103 (93.2%) sites, of whom 74 (77.1%) performed PET in patients with brain tumours. Reasons for not performing PET included limited availability of tracers (14/29, 48.3%), high cost (11/29, 37.9%), and PET perceived unnecessary (8/29, 27.6%). Of sites performing PET, 69/74 (93.2%) reported use in glioma, 58/74 (78.4%) in brain metastasis, 52/74 (70.3%) in meningioma, and 46/74 (62.2%) in CNS lymphoma. Amino acid PET was performed at 62/71 centres (87.3%; 3 not reported [n.r.]), most frequently in glioma (58/59, 98.3%, 3 n.r.) and for differentiation of treatment-related changes from tumour progression (58/59, 98.3%). Somatostatin receptor (SSTR) PET was performed at 50/68 sites (73.5%, 6 n.r.), mainly in meningioma (48/49, 98.0%), for patient selection before radioligand therapy (41/49, 83.7%) and for radiotherapy target volume definition (33/49, 67.3%). Unrestricted coverage by statutory health insurance was reported by 46/59 (78.0%) centres for amino acid PET and 33/49 (67.3%) for SSTR PET. CONCLUSION: PET use in neuro-oncology is variable across EORTC-BTG sites. Generation of evidence in clinical trials and surveys including non-academic institutions are needed to guide implementation in clinical practice.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Mair MJ, Lohmann P, Galldiks N, et al. Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey. Eur J Nucl Med Mol Imaging. 2025. PMID: 40464806. doi:10.1007/s00259-025-07366-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。